Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Humalog er større end risiciene ved behandling af diabetes mellitus.
The Committee for Medicinal products for Human Use (CHMP) decided that Humalog’ s benefits are greater than its risks for the treatment of diabetes mellitus.